Kevin Lin

Associate - Boston

Kevin Lin

Contact Information


Kevin Lin is an associate in Foley Hoag’s Business Department, working primarily in the Emerging Companies and Venture Capital Practice Group. Kevin’s practice focuses on working with emerging technology and life science companies throughout the corporate life cycle, including on early-stage formation and structuring matters, angel and venture financings, commercial transactions, mergers and acquisitions, and general corporate governance matters.

More »

Education:

  • Boston University School of Law, J.D., 2016
  • Cornell University, B.A., 2013

Languages:

English, Mandarin

Representative Experience

Venture Capital

  • Represented Alloy Therapeutics in a $75.0 million Series C Financing led by 8VC, Presight Capital and Peter Thiel.
  • Represented Zapata Computing, a quantum software company empowering enterprise teams to accelerate quantum solutions and capabilities, in closing its $38 million Series B financing, led by Comcast Ventures, Pitango and Prelude Ventures.
  • Represented RedShift BioAnalytics Inc., a company providing next-generation platform technology enabling measurement of previously undetectable structure changes in biomolecules, in closing its $20 million Series E Preferred Stock financing. 
  • Represented numerous venture capital firms in their portfolio investment activities.

Mergers and Acquisitions 

  • Represented global cannabis operator Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) in signing a definitive agreement to acquire Green Leaf Medical, LLC, a privately held, fully integrated cannabis multi-state operator based in the mid-Atlantic region, for approximately $240 million with the potential for additional performance-based milestone payments.
  • Represented Skillsoft in its acquisition of Pluma, a digital professional development and executive-quality coaching platform, for approximately $22 million.
  • Represented Ethos Cannabis, a multi-state cannabis operator, in connection with its acquisition of dispensaries in Pennsylvania and Maryland from 4Front Ventures Corp.
  • Represented NASDAQ-listed software company in its acquisition of a micro-app platform company for approximately $200 million. *

Strategic Transactions

  • Assisted biotechnology ecosystem company Alloy Therapeutics, Inc. with the formation of Broadwing Bio LLC, a joint venture with Maze Therapeutics, Inc., to develop targeted antibody therapies for the treatment of ophthalmic diseases.

*Prior to joining Foley Hoag

  • “Understanding the Chain of Liability Under HIPAA and How Business Associate Agreements Allocate Risk,” New Hampshire Bar News (January 2018)
  • Lead author, “Solo and Small Firm Cybersecurity Guide: Ethics and Data Security: What Are the Attorney’s Obligations,” New Hampshire Bar News (September 2017)
  • “Know the Law: Protect your company from cyber attacks,” New Hampshire Union Leader (March 2017)
  • Co-author, “Professional service companies face significant cyber risk,” New England In-House (February 2017); also published in New Hampshire Business Review (February 2017)
  • “Know the Law: Some data collecting requires disclosures,” New Hampshire Union Leader (December 2016)
  • Co-author, “Trends in M&A Provisions: Exclusion of Consequential Damages,” Mergers & Acquisitions Law Report, Bloomberg BNA (March 2014)
  • Lead author, “Basketball,” encyclopedia entry for Encyclopedia of Lying and Deception, SAGE Reference (March 2014)

Foley Hoag Alerts & Updates

Honors

  • Boston University Journal of Science and Technology Law, Note Editor

Involvement

  • Boston Bar Association
  • Massachusetts Bar Association
  • New Hampshire Bar Association
  • "Exit Strategies for Venture Capital Backed Companies," Angel Capital Association: New England Regional Meeting, 2021
Add to Bio Folder

Download Bio

Bar Admissions

  • Massachusetts
  • New York
  • New Hampshire

Court Admissions

  • U.S. District Court for the District of New Hampshire